India: Delhi High Court Promotes Indigenous R&D In The Pharmaceutical Industry: Novel Drug Delivery Systems Are Not Implicitly Included Under The Drugs (Price Control) Order, 2013

In the recent case of Modi-Mundipharma Private Limited v Union of India & Ors., (Writ Petition (Civil) No. 11802 of 2016), the High Court of Delhi (Court) has clarified that incremental innovation or novel drug delivery systems like lipid / liposomal formulations, sustained release, controlled release, etc. should be treated as scheduled formulations under Drugs (Price Control) Order, 2013 (2013 DPCO) only if specifically specified in the list. The Court held that such differential forms should be considered different for the purposes of procurement, pricing, policy.

Background

Modi-Mundipharma Private Limited (Petitioner) challenged the standing order dated 9 May 2016 (Standing Order) passed by the National Pharmaceutical Pricing Authority (NPPA) as it sought to include TRD Contin 100mg tablet CR 10 (Subject Formulation), within the scope of the ceiling price fixed for Tramadol tablet. The Petitioner being aggrieved by the Standing Order preferred a review under paragraph 31 of the 2013 DPCO, which was dismissed. The NPPA held that ceiling price of Tramadol 100mg tablet was fixed under Section 2.2.3 of the National List of Essential Medicines, 2015 (NLEM), which included all variants, including the Controlled Release (CR) and Sustained Release (SR) delivery systems.

Issue

Whether a formulation developed through incremental innovations like the CR / SR delivery systems will be included in Schedule I of the 2013 DPCO only if it is specified in the list against a medicine?

Submissions of the Petitioner

The Petitioner contended that the Subject Formulation is not included in the NLEM. As per Explanation (2) to Schedule I of the 2013 DPCO, formulations developed through incremental innovations like the SR / CR release systems are included in the NLEM only if specifically mentioned. The Subject Formulation uses a 'Continuous Controlled Release Dual Mechanism Drug Delivery System', which is an innovative drug delivery system and is not specifically mentioned in the NLEM. As a result, the Subject Formulation cannot be read as included in the NLEM. Consequently, it was submitted that the Subject Formulation is not a "scheduled formulation" within the meaning of the 2013 DPCO and is not subject to price fixation under the 2013 DPCO.

Respondent's Contention

The Respondent contended that the CR delivery system merely relates to strength and dosage and the non-inclusion of such strength and dosage would not mean that the Subject Formulation is outside the ambit of the 2013 DPCO. If the manufacturer combines, tweaks or modifies its product either in terms of a composition or on mode of administration, the same would not result in excluding the medicine from the purview of the price control regime under the 2013 DPCO. The Respondent further submitted that in matters concerning procurement and availability of essential medicines, the public interest is paramount and hence, the provisions of the 2013 DPCO must be interpreted in a manner which furthers public interest.

Observations and findings of the Court

The Court clarified that an explanation is an integral part of the statute and therefore in certain circumstances, the legislature explains the true purpose of a statute through an explanation. Similarly, in the present case the strength which is not specified in Schedule I of the 2013 DPCO, is to be considered as 'non-scheduled formulation' and must be understood in the basis of Explanation (1) and Explanation (2) of the 2013 DPCO. Accordingly, the Court made the following observations:

  • The true purpose of Explanation (1) to Schedule I of the 2013 DPCO is to extend the scope of Schedule I of the 2013 DPCO to include formulations with dosage forms different from those listed in Schedule I.
  • Explanation (2) of the 2013 DPCO clarifies that those formulations which are developed through incremental innovation or involve novel drug delivery systems such as the CR / SR delivery systems would not be included in the list unless specifically mentioned.
  • The Report of the Core Committee for Revision of National List of Essential Medicines 2015 (Core Committee Report) also elucidates that the Core Committee deliberated on dosage forms and formulations such as the SR delivery system, modified release and extended release and observed that any dosage form of the medicine, which does not have any significant difference in terms of pharmacokinetics or pharmacodynamics or efficacy-safety profile over the dosage form should be considered as included in Schedule I of the 2013 DPCO.
  • In view of Explanation (2) to Schedule I of the 2013 DPCO, formulations developed through incremental innovation or involving a novel drug delivery system would be considered materially different and cannot be read as to be included in the said Schedule unless the same are specified in the list.

The Court accordingly rejected the Respondent's contention that only new drugs, which fall within the scope of paragraph 32 of the 2013 DPCO are excluded from the ambit of price control, while the remaining medicines must be read as included in Schedule I of the 2013 DPCO irrespective of their dosage or delivery systems. In paragraph 32 of the 2013 DPCO, only new drugs which are developed by indigenous research and those which fall within the scope of paragraph 32 of the 2013 DPCO are excluded. The Court observed that a formulation which is excluded from the NLEM does not escape the rigour of the 2013 DPCO. However, if the formulations fall within the scope of paragraph 32 of the 2013 DPCO, the 2013 DPCO would have no application to such drugs.

Since, in the present case, it was not disputed whether the formulation manufactured by the Petitioner incorporates the CR delivery system, the Court held that the Subject Formulation manufactured by the Petitioner is not covered within the ambit of Schedule I of the 2013 DPCO and would not be subject to price fixation.

Comment

This judgement will be greatly welcomed by the pharmaceutical industry, which has of late being suffering from increasing costs, a regime seeking to control the price of innovative drug delivery systems, and the non-recognition of enhancements in therapeutic value under the guise of price fixation of scheduled drugs. By interpreting the true purpose of the 2013 DPCO through the observations made in the Core Committee Report, and differentiating the 2013 DPCO from the Drugs (Price Control) Order, 1995, the Court noted that the new regime now focusses on regulating the price of formulations, instead of regulating the price of bulk drugs. This observation ensures that a systematic approach is followed while adjudicating upon areas, which may prima facie appear to be ambiguous.

The Court by ensuring careful monitoring and differential pricing for different products has promoted indigenous research in the pharmaceutical industry, which otherwise may have reached a standstill, in wake of the strict price fixation norms. The Court has interpreted the provisions of the 2013 DPCO in a manner which will enhance the opportunities for innovation, enhancement of therapeutic value and further promote the growth of the pharmaceutical industry. The Court recognised that medicines developed through incremental innovation cannot be treated at par with other medicines because of the method of manufacture, the technology involved, the advanced benefits to patients and the advanced research and development preceding the manufacture of such medicines.

The content of this document do not necessarily reflect the views/position of Khaitan & Co but remain solely those of the author(s). For any further queries or follow up please contact Khaitan & Co at legalalerts@khaitanco.com

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
7 Aug 2018, Webinar, Mumbai, India

Justice B N Srikrishna Committee has released the draft Personal Data Protection Bill, 2018 (“Bill”) on 27 July 2018. The Bill (when enacted) will significantly reshape the data privacy and protection landscape for organisations in India as well as outside India that have certain India touchpoints.

 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions